Evidence map›Paper›PMID 39827353›Full record

ArticleLipids in health and disease2025

Prevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment.

Miguel Saraiva, Jonatas Garcez, Beatriz Tavares da Silva, Inês Poças Ferreira, José Carlos Oliveira, Isabel Palma

Abstract read
In one paragraph

Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Enhancing Post-Discharge Care for People Who Have Had an Acute Myocardial Infarction in Portugal: Insights From Patient Journey Mapping.Health expectations : an international journal of public participation in health care and health policy · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miguel SaraivaDepartment of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal. miguelsaraiva.md@gmail.com.
Jonatas GarcezDepartment of Clinical Chemistry, Local Health Unit of Santo António, Porto, Portugal.
Beatriz Tavares da SilvaDepartment of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal.
Inês Poças FerreiraDepartment of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal.
José Carlos OliveiraDepartment of Clinical Chemistry, Local Health Unit of Santo António, Porto, Portugal.
Isabel PalmaDepartment of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) is a major cause of mortality worldwide, necessitating more refined strategies for risk assessment. Recently, lipoprotein(a) [Lp(a)] has gained attention for its distinctive role in atherosclerosis, yet its prevalence and impact for cardiovascular risk assessment are not well-documented in the Portuguese population. This study aimed to characterize Lp(a) levels in a real-world Portuguese cohort, investigating its prevalence and association with CVD risk.

methodsRetrospective and cross-sectional study of adults who underwent serum Lp(a) analysis in a Portuguese hospital between August 2018 and June 2022. Demographic and anthropometric data, laboratory values, relevant comorbidities and lipid-lowering medication were collected.

resultsOf 1134 participants, 28.7% had elevated Lp(a) levels (> 125 nmol/L). A higher prevalence was observed in those with atherosclerotic cardiovascular disease (ASCVD) (45.9%) or a family history of premature CVD (41.9%). Additionally, a significant association was found between elevated Lp(a) levels and traditional CVD risk factors, including hypertension, dyslipidemia, and diabetes mellitus. Among those classified as having low-to-moderate CVD risk by (Systematic COronary Risk Evaluation 2) SCORE2, 55.7% exhibited high Lp(a) levels (> 75 nmol/L), suggesting a potential higher risk of CVD disease.

conclusionsThe prevalence of elevated Lp(a) in Portugal, notably among those with ASCVD or premature CVD history, is concerning. This study underscores the potential of Lp(a) assessment for a more comprehensive approach to cardiovascular risk assessment. This could improve the stratification of CVD risk and identify individuals who could benefit from early intensive management of their risk factors, ultimately reducing the burden of CVD and cardiovascular-related mortality.

Indexed as

Cardiovascular DiseasesLipoprotein(a)AdultAgedAtherosclerosisCross-Sectional StudiesDyslipidemiasFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPortugalPrevalenceRetrospective StudiesRisk AssessmentLipoprotein(a)Cardiovascular diseaseDyslipidemiaLipoprotein aReal-world evidenceRisk assessment

Identifiers

PMID39827353
PMCPMC11742203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.